Metatranscriptome analysis of the vaginal microbiota reveals potential mechanisms for protection against metronidazole in bacterial vaginosis

Zhi-Luo Deng[a#], Cornelia Gottschick[a*], Sabin Bhuju[b], Clarissa Masur[c], Christoph Abels[c], and Irene Wagner-Döbler[a]

[a] Research Group Microbial Communication, Department of Medical Microbiology, Helmholtz Centre for Infection Research, Inhoffenstr. 7, 38124 Braunschweig, Germany

[b] Genome Analytics, Helmholtz Centre for Infection Research, Inhoffenstr. 7, 38124 Braunschweig, Germany

[c] Dr. August Wolff GmbH & Co. KG Arzneimittel, Sudbrackstrasse 56, 33611, Bielefeld, Germany

Running title: Activity profiling of the vaginal microbiota

Address correspondence to Zhi-Luo Deng, Zhiluo.Deng@helmholtz-hzi.de

Z.-L.D. and C.G. contributed equally to this work.

[*] Present address: Institute for Medical Epidemiology, Biometrics and Computer Science, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany

Abstract

Bacterial vaginosis (BV) is a prevalent multifactorial disease of women in their reproductive years characterized by a shift from the *Lactobacillus* spp. dominated microbial community towards a taxonomically diverse anaerobic community. For unknown reasons, some women do not respond to therapy. In our recent clinical study, out of 37 women diagnosed with BV, 31 were successfully treated with metronidazole, while 6 still had BV after treatment. To discover possible reasons for the lack of response in those patients, we performed a metatranscriptome analysis of their vaginal microbiota, comparing them to patients who responded. Seven out of 8 Cas genes of *Gardnerella vaginalis* were highly up-regulated in non-responding patients. Cas genes, in addition to protecting against phages, might be involved in DNA repair thus mitigating the bactericidal effect of DNA damaging agents like metronidazole. In the second part of our study, we analyzed the vaginal metatranscriptomes of four patients over three months and showed high *in vivo* expression of genes for pore-forming toxins in *L. iners* and of genes encoding enzymes for the production of hydrogen peroxide and D-lactate in *L. crispatus.*

35 **Importance**

36 Bacterial vaginosis is a serious issue for women in their reproductive years. Although it can
37 usually be cured by antibiotics, the recurrence rate is very high, and some women do not
38 respond to antibiotic therapy. The reasons for that are not known. Therefore we undertook a
39 study to detect the activity of the complete microbiota in the vaginal fluid of women that
40 responded to antibiotic therapy and compared it to the activity of the microbiota in women
41 that did not respond. We found that one of the most important pathogens in bacterial
42 vaginosis, *Gardnerella vaginalis*, has activated genes that can repair the DNA damage caused
43 by the antibiotic in those women that do not respond to therapy. Suppressing these genes
44 might be a possibility to improve the antibiotic therapy of bacterial vaginosis.

45

46 ## Introduction

47 The healthy vaginal microbiome is characterized by low pH and low diversity and can be
48 categorized into community state types (CSTs) that are dominated by different *Lactobacillus*
49 spp. such as *L. crispatus*, *L. iners*, *L. gasseri* and less frequently *L. jensenii* or a more diverse
50 community (1). Bacterial vaginosis (BV) is a frequent multifactorial disease of women in
51 their reproductive years that is characterized by a shift of this *Lactobacillus* spp. dominated
52 bacterial community to a community of various mostly anaerobic bacteria (2). BV is
53 associated with a higher risk of preterm birth and of acquiring sexually transmitted infections
54 such as HIV (3). The most common bacteria found in BV, identified by 16S rRNA gene
55 sequencing, are *Gardnerella*, *Atopobium*, *Prevotella*, *Bacteroides*, *Peptostreptococcus*,
56 *Mobiluncus*, *Sneathia*, *Leptotrichia*, *Mycoplasma* and BV associated bacterium 1 (BVAB1) to
57 BVAB3 of the order Clostridiales. Recently, three CSTs dominated by *Gardnerella vaginalis*,
58 Lachnospiraceae and *Sneathia sanguinegens*, respectively, have been described (4). In our
59 recent clinical study *S. amnii* was identified as the best biomarker for BV (5).

60 The most important pathogen in BV is *Gardnerella vaginalis* (6). It is currently the only
61 described species in the genus *Gardnerella*, but genome comparisons suggest that it can be
62 separated into four genetically isolated subspecies (7). While they cannot be resolved by 16S
63 rRNA gene sequencing, the universal target from the chaperonin-60 gene separates the
64 species into the same four subgroups (group A, clade 4; subgroup B, clade 2; subgroup C,
65 clade 1; subgroup D, clade 3) (6,8,9). All four subgroups of *G. vaginalis* can be detected in
66 the vaginal microbiota of healthy women throughout the menstrual cycle (10). Subgroup A
67 and C define distinct CSTs in health (11). Isolates from the four subgroups of *G. vaginalis*
68 differ in their virulence as well as in their resistance against metronidazole. The sialidase
69 activity of *G. vaginalis* is an important virulence factor and it was detected in all isolates from

70 subgroup B and few isolates of subgroup C but not in subgroups A and D isolates (12). The
71 presence of sialidase activity is used for diagnosis of BV in a commercial kit (13). Resistance
72 against metronidazole was found in subgroups A and D isolates, while those from subgroups
73 B and C were highly susceptible (14).

74 Metronidazole is a widely applied chemotherapeutic agent used to treat infectious diseases
75 caused by anaerobic bacteria, and it is the first-line antibiotic for treating BV (15,16).
76 Metronidazole is a prodrug which requires enzymatic reduction within the cell, which occurs
77 under anaerobic conditions only, to transform it into an active form (17). Activated
78 metronidazole acts by covalently binding to DNA, disrupting its helical structure and causing
79 single and double strand breaks that lead to DNA degradation and death of the pathogens
80 (17). Resistance can therefore be mediated by lack of activation of the prodrug, or by repair of
81 DNA damage, and has been studied in various pathogens. In *Helicobacter pylori* and
82 *Campylobacter spp.* ferredoxin, ferredoxin/ferredoxin-NADP reductase (FNR) and
83 nitroreductase contribute to metronidazole resistance (17). In *Bacteroides fragilis*, genes
84 responsible for DNA repair like recA and recA-mediated autopeptidase (Rma) and a gene
85 named nitroimidazole resistance gene (*nim*) encoding a nitroimidazole reductase were shown
86 to confer resistance against metronidazole (18,19). Failure of BV treatment by metronidazole
87 is relatively rare (5,20).It is unclear if it is caused by resistance of the BV pathogens to
88 metronidazole, and which mechanisms are acting *in vivo*. A recent study has demonstrated
89 that failure of treatment of BV with metronidazole is not associated with higher loads of *G.*
90 *vaginalis* and *A. vaginae* (21). Isolates from *G. vaginalis* subgroups A and D are intrinsically
91 resistant against metronidazole, but the underlying mechanism is unknown (14).

92 Until now, the majority of studies regarding the vaginal microbiota have focused on 16S
93 rRNA gene sequencing, answering only questions on the taxonomic composition of bacterial

94 communities but not on their functions (2). A metatranscriptome analysis comparing vaginal
95 swabs from two women with BV with two healthy subjects showed that *L. iners* upregulates
96 transcription of the cholesterol-dependent cytolysin (CDC) and of genes belonging to the
97 clustered regularly interspaced short palindromic repeats (CRISPR) system in BV (22). No
98 study has investigated the activity shifts of the vaginal microbiota during antibiotic treatment
99 of BV.

100 We had previously analyzed the vaginal microbiota in the context of a clinical trial using 16S
101 rRNA gene sequencing (5). Of 37 patients diagnosed with BV and included in this study, 31
102 were initially cured by a single oral dose of metronidazole. Six patients did not respond, i.e.
103 they were still diagnosed with BV according to Nugent score after antibiotic therapy. Here we
104 asked if differences in the activity of the microbiota might be responsible for the lack of
105 response in those six patients. We therefore analyzed their metatranscriptomes at the time of
106 diagnosis of BV (visit 1) and after treatment with metronidazole (visit 2) and compared them
107 to those of 8 patients that responded to treatment according to Nugent score.

108 The high rate of recurrence is another crucial problem for BV treatment. The one-year
109 recurrence rate of BV ranges from 40% to 80% after therapy with metronidazole (23) or
110 clindamycin cream (24). CST dominated by *L. iners* might have an increased probability to
111 shift to a dysbiotic state (22,25,26). In the second part of our study, we therefore followed the
112 activity of the microbiota from four of the patients that initially responded to metronidazole
113 treatment over a period of 3 months (visit 3-5) and analyzed gene expression of *L. crispatus*
114 and *L. iners* in *vivo*.

115 We show the importance of *G. vaginalis* for BV, which can be massively underestimated
116 using 16S rRNA gene sequencing. The relative abundance of the four subgroups of *G.*
117 *vaginalis* could be determined in responders and non-responders. Transcripts potentially

118 leading to lack of response to metronidazole treatment were identified. CRISPR-Cas genes are
119 suggested as a novel mechanism of *G. vaginalis* to mitigate the DNA damaging effect of
120 metronidazole. *L. iners* highly expressed genes for pore-forming toxins *in vivo*, and in *L.*
121 *crispatus* the most highly expressed transcripts *in vivo* encoded enzymes for D-lactate and
122 hydrogen peroxide production.

123

124 # Results

125 **Study population and overview of sequencing results**

126 We studied the vaginal microbiome of 14 patients during and after metronidazole treatment of
127 BV using metatranscriptome sequencing (Fig. 1A). Patients were part of a clinical trial
128 described elsewhere (5). In the first part of the study, we analyzed samples from two
129 timepoints (diagnosis of BV, visit 1) and after metronidazole treatment (visit 2). Eight patients
130 responded to treatment, and six patients did not respond to treatment with the antibiotic, so
131 were still BV positive according to Nugent score at visit 2. In the second part of our study,
132 three additional timepoints were analyzed for four of the patients that initially responded to
133 metronidazole therapy, covering a total period of 3 months. Those four patients belonged to
134 the lactic acid arm of the clinical study. Two of them experienced recurrence, while the other
135 two were stably non-BV after treatment according to Nugent score (details in Table S1 sheet
136 1). In total, we analyzed 40 vaginal fluid samples, 22 with BV status and 18 without.
137 Metatranscriptome sequencing resulted in a total of 1,879,945,342 reads. Of these,
138 1,377,516,082 reads (73%) were left after quality filtering and removal of ribosomal RNA
139 (Table S1 sheet 2). On average, 34 million reads were analyzed per sample.

140 **Construction of the reference genome and gene databases for taxonomic and activity**
141 **profiling**

142 Human reads comprised ~11% (BV) versus ~56% (non-BV) of the total putative mRNA reads
143 based on the standard Kraken (27) database (Table S1 sheet 2). This suggests that the
144 bacterial load is much lower in non-BV than in BV since the human contamination is much
145 higher in non-BV. Using the standard Kraken database, only 41% of total putative microbial
146 (non-human) mRNA reads could be assigned taxonomically (Table S1 sheet 2). To improve
147 the fraction of taxonomically assignable reads we then constructed a refined database
148 (ref_Genome) which combined the urogenital subset of the HMP (28) database (147
149 genomes) and all species which are not included in the urogenital subset of the HMP database
150 but detected by the standard Kraken database with an abundance >1% (7 genomes). We also
151 added *S. amnii* and *S. sanguinegens* which had previously been shown to be highly abundant
152 based on 16S rRNA gene sequencing (5) but were not contained in either HMP or the
153 standard Kraken reference database. There are four *G. vaginalis* strains in the HMP database,
154 of which one belongs to subgroup A and three belong to subgroup C. Given the importance
155 and high intra-species diversity of *G. vaginalis*, we added 5 additional *G. vaginalis* genomes
156 based on the genome tree reported in the NCBI database and the completeness of the genome
157 assembly; these five strains cover all four subgroups. We added the genomes of *Gardnerella*
158 sp. 26-12 and *Gardnerella* sp. 30-4 which were isolated from the bladder recently (29). They
159 were classified into *G. vaginalis* subgroup A based on sequence homology (29). In total, this
160 database contained 163 bacterial genomes from 105 species (Table S1 sheet 3). Using this
161 database, the rate of taxonomically classified putative microbial mRNA reads could be
162 improved to 86% on average (Table S1 sheet 2).

163 For functional assignment, we constructed a reference gene database (ref_Gene) (Table S1
164 sheet 4). It was based on the same genomes as the ref_Genome database, except that the seven
165 additional *Gardnerella* spp. genomes were not included because of the low quality of the
166 annotation of coding sequences. The ref_Gene database contained 301,323 genes. To
167 investigate the activity shifts of the communities, we mapped the cleaned metatranscriptomic
168 reads to the ref_Gene database using BWA. In total, 78% of total putative microbial mRNA
169 reads could be mapped to the ref_Gene. Per sample, on average 8.9 million microbial mRNA
170 reads could be mapped with MAPQ >10 (Table S1 sheet 2).

171 **Shifts in the taxonomic composition of the active community following metronidazole**
172 **treatment**

173 The taxonomic composition of transcripts was determined using Kraken and the ref_Genome
174 database. Fig. 1B shows that in all communities with BV status the most abundant species
175 were *G. vaginalis*, *A. vaginae*, *S. amnii* and *Prevotella timonensis* In the post treatment
176 communities from responders (non-BV, Nugent score <6) the metatranscriptomes were
177 dominated by *L. crispatus*, *L. iners* and *L. jensenii*, representing typical CSTs of the healthy
178 female microbiota.

179 On average less than 14 species contributed >90% of the mapped reads in BV and 3 species
180 accounted for >90% of the mapped reads in non-BV (Fig. 1C). The individual dominance
181 plots showed the same pattern where 10 species contributed >90% of the metatranscriptomes
182 for most patients in BV. In non-BV, this number was 2 for most patients and the dominance
183 curves were extremely steep. For comparison, in the periodontal metatranscriptome more than
184 100 species were required to cover 90% of mapped reads (30). These data show that the active
185 microbiota in BV is much less diverse than suggested by 16S rRNA gene sequencing.

186 *G. vaginalis* was the most dominant active species in BV. To estimate the relative abundance
187 of the four subgroups of *G. vaginalis*, we extracted all reads assigned to *G. vaginalis* from the
188 metatranscriptomes and assigned them to the four strains representing subgroups A-D,
189 respectively (409-05, 00703Bmah, HMP9231, 00703Bmash) using Kraken. For this analysis,
190 we used samples from visit 1 where *G. vaginalis* reads comprised at least 20% of all reads,
191 which included all 6 patients without response to treatment, and 5 of the 8 patients that
192 responded to treatment. Figure 1D shows that on average >95% of the reads could be mapped
193 to the four subgroups and only on average 7% were assigned ambiguously. In those patients
194 that did not respond to treatment, subgroups A and D comprised 68.5±17.2 % of all reads,
195 while they accounted for 30.5±29.3% of all reads in patients that responded to treatment
196 (Wilcoxon test P=0.0520). We observed that *Gardnerella* spp. previously isolated from the
197 bladder (*Gardnerella* sp. 26-12 and *Gardnerella* sp. 30-4) (29) contributed on average 6% of
198 all taxonomically assigned reads in BV (Fig. S1).

199 **Comparison of the taxonomic composition of vaginal fluid samples between**
200 **metatranscriptome and 16S rRNA gene sequencing**

201 We compared the taxonomic composition determined using 16S rRNA sequencing previously
202 (5) and the taxonomic composition of the metatranscriptome determined here by Kraken with
203 the ref_Genome database. In non-BV, we did not observe any considerable difference for the
204 four most abundant species (Table S1 sheet 6), while in BV large differences between the two
205 datasets were found. Fig. 2 shows the top 12 most abundant taxa identified using 16S rRNA
206 gene sequencing and metatranscriptomics, respectively. Most of the abundant species
207 identified in the mRNA sequencing data set were also identified using 16S rRNA gene
208 amplicon sequencing, although usually at different abundances. For example, *A. vaginae*
209 comprised 13% of all reads based on 16S rRNA gene sequencing, but only 11% in the

210 metatranscriptome dataset. The most pronounced difference was observed for *G. vaginalis*
211 which comprised on average 47% of relative abundance in the metatranscriptome and on
212 average only 5% in the 16S rRNA sequencing data. Several additional differences were
213 found: Higher level taxa like Veillonellaceae (family) or *Parvimonas* (genus) are not listed
214 among the top 12 taxa of the metatranscriptome, because mapping occurred to species level,
215 and the abundance of individual species of these higher order taxa was too low to be found
216 among the top 12 taxa (Table S1 sheet 6). BVAB2 is readily detected by PCR and is an
217 important indicator of BV, but it is not yet cultivated and so there is no genome available to
218 map the reads against.

219 **Global community profiling in non-BV and BV**

220 In order to profile the function of the communities, all cleaned putative mRNA reads (Table
221 S1 sheet 2) were mapped using BWA onto the ref_Gene database annotated with KEGG
222 ortholog (KO) genes. We used principal component analysis (PCA) to visualize the difference
223 between the microbiota in BV and non-BV on the level of taxonomy (16S rRNA gene) (Fig.
224 3A), taxonomic composition of expressed genes (metatranscriptome) (Fig. 3B) and functional
225 annotation of transcripts to KEGG orthologues (KO genes) (Fig. 3C). Figure 3A shows that
226 the non-BV communities form a tight cluster on the level of the 16S rRNA sequencing, while
227 BV communities vary, in accordance with the studies using amplicon sequencing of BV. *L.*
228 *iners*, *Prevotella* spp., *G. vaginalis*, *A. vaginae* and *S. amnii* drive the separation between non-
229 BV and BV On the level of the taxonomic composition of the metatranscriptomes (Fig. 3B)
230 this pattern was reversed; samples from non-BV were much more heterogeneous than those
231 from BV. The non-BV communities clustered into two groups dominated by *L. iners* and *L.*
232 *crispatus* respectively, whereas *G. vaginalis*, *A. vaginae* and *S. amnii* were abundant in BV.
233 This reversal is even stronger on the level of KO genes (Fig. 3C): Samples from BV form a

234 tight cluster, while those from non-BV vary widely. It is the opposite pattern than that found
235 for the phylogenetic marker gene. The KO genes that contributed most to these differences in
236 non-BV were phosphofructokinase isozyme *pfkA* (31) and ribosomal protein coding genes
237 *rpsI*, *rpmF* and *rplU* (32,33). In BV, *msmE*, *cycB* and *pflD* genes that encode proteins
238 involved in carbohydrate uptake and metabolism (34,35) were stably higher expressed.

239 ***In vivo* expression of putative metronidazole resistance associated genes in *G. vaginalis***

240 To clarify the possible contribution of genes related to metronidazole resistance in Gram
241 positive pathogens to the difference in response to treatment of the vaginal microbiota, we
242 examined their expression (Table S1 sheet 9) in *G. vaginalis.* For this analysis, BV
243 communities from 11 patients at visit 1 were analyzed in which the level of *G. vaginalis*
244 transcripts was >20%. Six of these patients did not respond to treatment and five responded.
245 Although *A. vaginae* and *S. amnii* are also key players in BV we could not analyze them here
246 since there were too few samples dominated by them. As shown in Fig. 4A, there was no clear
247 expression pattern for most of these genes (detailed data in Table S1 sheet 9). The only
248 significantly changed gene expression was that of the gene encoding ferredoxin which was
249 less active in *G. vaginalis* in non-responding patients (fold change=1.67, Wilcoxon test
250 P=0.00866 based on relative abundance = read count of given genes of *G. vaginalis* / read
251 count of *G. vaginalis* %).

252 **CRISPR associated protein coding genes of *G. vaginalis* were strongly up-regulated in**
253 **vaginal fluids of patients not responding to treatment**

254 We then performed a global analysis of differential expression of KO genes of *G. vaginalis* in
255 these same communities (visit 1, 11 BV samples with >20% transcripts from *G. vaginalis*
256 including 6 patients that did not respond to treatment and 5 that responded). We observed that

257 there were 9 KO genes highly up-regulated with FDR <= 0.05 (log2 fold change up to 9.46)
258 in communities without response. Strikingly, among the most strongly up-regulated KO
259 genes, seven were *cas* genes (36) (Fig. 4B). In total there were 8 different *G. vaginalis*
260 CRISPR-associated (Cas) genes found in the genomes, namely *cas*1-3, *cas*A-E, of which
261 seven were up-regulated (*cas*1-3, *cas*A-D).

262 There were 9 KO genes down-regulated but the fold change values were not as high as for the
263 up-regulated genes. *fucP* (fucose permease) was identified as the most strongly down-
264 regulated gene with a log2 fold change of -4.24.

265 **Time course of activity profiles and recurrence**

266 In the second part of our study, we analyzed the metatranscriptome of vaginal fluid samples
267 from four of the patients that initially responded to therapy with metronidazole for the
268 complete duration of the clinical trial. Two of these patients experience recurrence of BV, and
269 two remained stably non-BV. Five timepoints were analyzed of which the first two were
270 already shown in Fig. 1A. They represented acute BV (visit 1) and after metronidazole
271 therapy (visit 2). Here, we also show visit 3-5, which were all non-BV, with the exception of
272 recurrence at visit 5 in patient 04_001 and at visit 3 in patient 06_004. Fig. 5A shows the
273 taxonomic composition of the communities. In one of the two patients that stably maintained
274 a non-BV status *L. crispatus*, and in the other *L. iners* dominated the microbiota. The
275 principal components analysis of the activity profiles is shown in Fig. 5B. In acute BV,
276 samples from all four patients clustered together (red circle). After the treatment, samples
277 from patient 08_006 who was stably non-BV moved into a very dense and distinct cluster
278 (illustrated by the arrow 1 and enclosed by a green circle). Samples from patient 13_019 who
279 also remained stably non-BV moved to a different cluster after treatment, shown by arrow 2
280 and encircled blue.

281 The activity shifts in patient 06_004, who experienced recurrence at visit 3, were especially
282 noteworthy: After treatment, the community moved towards an activity profile distinct from
283 all others (arrow 3). The recurrence of BV caused the community to shift back to the BV
284 cluster (red circle, arrow 4). At visit 4, the community moved to the non-BV cluster (blue
285 circle) and the patient became non-BV according to the Nugent score. We speculate that there
286 was an unknown intervention after visit 3 which changed the microbiome but this was not
287 recorded. Interestingly, the other case of recurrence (patient 04_001) had a different
288 progression. From visit 2 to 4, patient 04_001 was non-BV and these samples clustered
289 together in the "non-BV" cluster indicated by the blue circle. At visit 5, however, patient
290 04_001 had recurrent BV and the community shifted back again to the BV cluster.

291 **Transcriptomics of *L. iners* and *L. crispatus in vivo***

292 The stable colonization of the vaginal fluid of two patients that responded to antibiotic
293 therapy with either *L. iners* or *L. crispatus* allowed us to profile their gene expression *in vivo*
294 to gain more understanding of their different roles in the vaginal microbiota. We extracted the
295 reads mapped on *L. crispatus* in patient 08_006 (timepoint b-e) and *L. iners* in patient 13_019
296 (timepoint b-e) and performed a differential expression (DE) analysis using edgeR to compare
297 their activity profiles based on their KO genes comparing the expression of KO genes of *L.*
298 *crispatus* in *L. crispatus* dominated samples (n = 4) with the expression of KO genes of *L.*
299 *iners* in *L. iners* dominated samples (n = 4). The Venn diagram in Fig. 5C shows that the two
300 species share 569 KO genes, while 58 are unique to *L. iners* and 244 are unique for *L.*
301 *crispatus*, indicating *L. crispatus* possesses far more diverse functions than *L. iners.* The DE
302 analysis identified 654 significantly differentially expressed KO genes, of which 393 were up-
303 regulated in *L. crispatus* (Table S1 sheet 8). Among the top 100 most differentially expressed
304 KO genes in terms of FDR value, 64 were up-regulated in *L. crispatus*, Remarkably, genes

305 encoding enzymes involved in the production of H_2O_2 (pyruvate oxidase, NADH oxidase,
306 glycolate oxidase) (37,38) were highly expressed in *L. crispatus* (Table S1 sheet 8, KO genes
307 colored in blue). D-lactate dehydrogenase (K03778) was the most highly expressed gene in *L.*
308 *crispatus* (log2 CPM = 13.3, Table S1 sheet 8, colored in light green) and this gene is absent
309 in the genome of *L. iners*. On the other hand, we found that inerolysin (INY) was highly
310 expressed (log2 CPM =9.8) in *L. iners*, but absent in the genome of *L. crispatus* (Table S1
311 sheet 8, colored in red). Interestingly, we also found the orthologous gene (K11031) of
312 inerolysin known as vaginolysin (39) highly expressed in *G. vaginalis* (details in Table S1
313 sheet 7). Hemolysin C, another pore forming toxin, was highly expressed (log2 CPM = 9.8) in
314 *L. iners* but absent in *L. crispatus*.

315 **Discussion**

316 The aim of this study was to identify activity patterns in the vaginal fluid microbiota in BV
317 and after metronidazole therapy. In particular, we compared the transcriptional profiles of *G.*
318 *vaginalis* in vaginal microbiota from patients who did and did not respond to metronidazole
319 treatment, respectively. This is the first study to investigate the activity alterations of the
320 vaginal microbiota from patients with BV during treatment with the antibiotic metronidazole
321 using the metatranscriptomics approach. We found several changes in gene expression in non-
322 responding patients that might contribute to resistance against metronidazole by either not
323 activating the pro-drug or repairing DNA damage.

324 *G. vaginalis* was the most dominant active species in BV. *G. vaginalis* can be divided into
325 four phylogenetic subgroups which may in the future be described as subspecies and which
326 differ in virulence and susceptibility to metronidazole (6,12). We found transcripts from all
327 four subgroups in all patients, as previously shown based on sequencing of the universal
328 target cp-60 gene (6,9,11). Interestingly, in those patients that did not respond to treatment,

329 *Gardnerella* subgroups A and D which are resistant to metronidazole (14) were slightly more
330 abundant.

331 Sequencing of phylogenetic marker genes like the 16S rRNA gene or the cpn60 universal
332 target is a fast and sensitive method to profile the microbiota composition, but it does not
333 provide functional information and is prone to PCR bias. Moreover, DNA from dead cells
334 might also be detected. Therefore, we compared the taxonomic composition of the transcripts
335 with that of the 16S rRNA genes determined previously in those samples (5). We observed
336 that *G. vaginalis* comprised on average 47% of all transcripts in BV, while only 5% of 16S
337 rRNA genes were assigned to this species. This suggests that *G. vaginalis* is transcriptionally
338 more active than other vaginal bacteria; moreover, the commonly used 27F primer was
339 previously shown to underrepresent *G. vaginalis* (40). Other differences between the two
340 methods are caused by the low taxonomic resolution of the 16S rRNA gene, especially of
341 short amplicons, where a large fraction of 16S rRNA reads is assigned to higher level taxa,
342 e.g. genus or family. By contrast, the metatranscriptome reads are mapped to genomes and so
343 have species level resolution. Finally, transcripts can only be mapped if a genome is available.
344 If the species in question has not yet been cultivated, as for example the BVAB strains, then
345 reads cannot be assigned. In the periodontal pocket microbiota, about 50% of all reads cannot
346 be mapped to any bacterial genome (30). By contrast, the vaginal microbiota is much less
347 diverse and most of its representatives have been cultivated; using the improved ref_Genome
348 database, we were able to map 86% of all reads, indicating that uncultivated taxa did not
349 contribute very significantly to the active community in BV and after metronidazole therapy.

350 Low diversity in health and high diversity in BV is a hallmark of BV and it is so striking that
351 it has even been suggested to use diversity indices based on PCR amplified 16S rRNA genes
352 in addition to the clinical diagnosis based on Amsel criteria and Nugent score (4,41-43). Our

353 comparison between communities in BV and after metronidazole therapy on the levels of (1)
354 16S rRNA gene, (2) taxonomic composition of total transcripts, and (3) functional profiling
355 based on KO genes shows a reversal of this observation: BV communities, although highly
356 diverse on the taxonomic level, cluster tightly together on the functional level of KO genes.
357 On the contrary, non-BV communities are similar on the taxonomic level, but highly diverse
358 among individuals on the functional level.

359 In our metatranscriptome analysis we found evidence for mechanisms that hinder the
360 activation of the metronidazole prodrug, or mitigate the damage that metronidazole inflicts on
361 DNA, and thus could be important reasons for the lack of response in some women.

362 We show that the ferredoxin gene of *G. vaginalis* was less active in those patients that did not
363 respond to metronidazole. As an electron carrier, ferredoxin is downregulated in *H. pylori*
364 bacteria grown in the presence of metronidazole (17). It is required for activation of the
365 prodrug in *H. pylori* (44) and might have a similar role in *G. vaginalis*. Lack of response
366 might result from lack of activation of the prodrug. Unexpectedly, the nitroimidazole
367 resistance (*nim*) gene, which has been shown to mediate resistance to metronidazole in *B.*
368 *fragilis* by transforming metronidazole to a non-toxic amino derivative (16) was not highly
369 expressed in non-responders. This could be due to technical problems, since the Nim protein
370 sequence contains only partial CDS (https://www.ebi.ac.uk/ena/data/view/AGN03877).
371 Moreover, *nim*-negative strains of *B. fragilis* can tolerate high levels of metronidazole
372 indicating the importance of other mechanisms of resistance (16).

373 Remarkably, *cas* genes of *G. vaginalis* were highly up-regulated in samples from patients that
374 did not respond to metronidazole treatment. The CRISPR-Cas genes are present in about half
375 of all Bacteria and most Archaea (45); they represent a mechanism of adaptive immunity
376 which protects the prokaryotic cell against foreign DNA and has been developed into a

377 universal tool for genome editing (46). The *cas* genes of *G. vaginalis* belong to the *E. coli*
378 subtype and were found in about half of the clinical isolates (36). Their up-regulation might
379 reflect increased phage attacks in BV. Phages have been hypothesized to be crucial for the
380 etiology of BV by causing the collapse of *Lactobacillus* populations (47); accordingly, *L.*
381 *iners* upregulates its CRISPR-Cas system in BV (22). More than 400 annotated prophage
382 sequences were found in 39 *Gardenerella* strains (29). They might be induced to enter the
383 lytic cycle by the change in pH accompanying the shift to BV. However, the viral transcripts
384 contributed 0.1% of the total metatranscriptome in both non-responders and responders before
385 treatment.

386 The upregulation of CRISPR-Cas system genes in *G. vaginalis* from those patients that did
387 not respond to treatment by metronidazole suggests that the CRISPR-Cas system might have a
388 role in mitigating the DNA damaging effect of metronidazole. In addition to providing
389 adaptive immunity, CRISPR-Cas systems can have various additional functions (48) and it
390 was shown that they can protect the cell against DNA damaging agents (49). The Cas1
391 enzyme of *E. coli* (YgbT) physically and genetically interacts with the DNA repair system
392 (RecBC, RuvB) and is recruited to DNA double strand breaks; moreover, YgbT is necessary
393 for resistance of *E. coli* to DNA damage caused by the genotoxic antibiotic mitomycin C or
394 UV light (49). Our findings suggest that the CRISPR-Cas system may protect the vaginal
395 microbiota against the DNA damaging effect of metronidazole. If experimentally confirmed,
396 this finding might open a new path to fight bacterial resistance against DNA damaging agents.
397 For example, it would be worth testing if the susceptibility to metronidazole can be modified
398 in *Gardnerella* isolates and possibly other vaginal pathogens according to the expression level
399 of *cas* genes. It is not known how up-regulation of *cas* genes is regulated in the vaginal
400 microbiota. It might be a response to phage attack, thus by suppressing *cas* genes the

401 susceptibility to phages might be increased simultaneously with the susceptibility to
402 metronidazole. Using CRISPR engineered phages for therapy of dysbiotic communities has
403 been considered as one of many options of new therapeutic strategies based on a deeper
404 understanding of the human microbiome (50).

405 *L. iners* and *L. crispatus* dominate their respective CST in the healthy vaginal microbiota.
406 There were many factors observed by laboratory or genomic studies (37,51,52) which suggest
407 that more protection against dysbiosis is provided by *L. crispatus* rather than by *L. iners*. Here
408 we analyzed which genes are actually highly expressed *in vivo*: We observed that genes
409 encoding proteins for the production of H_2O_2 and D-lactic acid were highly expressed in *L.*
410 *crispatus.* H_2O_2 inhibits BV associated bacteria, but it has been questioned if its level in the
411 vaginal milieu is high enough, and it was suggested that lactic acid is more protective (53). In
412 *L. iners*, the genes for the pore-forming toxins inerolysin and hemolysin C were highly active,
413 supporting the hypothesis that *L. iners* may play an ambiguous role in the vaginal econiche
414 and is associated with vaginal dysbiosis (26,54).

415

416 **Conclusions**

417 This first study of the *in vivo* transcriptional activity of vaginal fluid microbiota during
418 metronidazole treatment of BV focused on possible reasons for the lack of response to
419 antibiotic therapy in some patients. Genes related to activation of the prodrug and repairing
420 the DNA damage caused by metronidazole were shown to be differentially expressed in
421 responders and non-responders. A completely new role for Cas proteins is hypothesized
422 which warrants closer inspection and may help to develop more efficient novel therapies to
423 improve the treatment of BV.

424

425 ## Material and Methods

426 ### Study design

427 Vaginal fluid samples of women analyzed here were a subset of the samples obtained during a
428 randomized controlled clinical trial described previously (5). The trial protocol was approved
429 by the local ethics committee (Ärztekammer Nordrhein - Medical Association North Rhine)
430 and written consent was obtained from all participants. The clinical trial was conducted in
431 accordance with the Declaration of Helsinki on Ethical Principles for Medical Research
432 Involving Human Subjects. Principles and guidelines for good clinical practice were followed.
433 The study was registered on ClinicalTrials.gov with the identifier NCT02687789. Briefly,
434 women were included into the clinical trial if they were BV positive according to Amsel
435 criteria and Nugent score and were biofilm positive on vaginal epithelial cells and positive for
436 extracellular polysaccharides (EPS) in urine. For treatment of acute BV, they received 2 g of
437 metronidazole orally and were afterwards treated with an intravaginal pessary for three weeks,
438 twice a week. Samples were taken during acute BV (visit 1), after receiving metronidazole 7
439 to 28 days after visit 1 (visit 2), after pessary application one week after visit 2 (visit 3), after
440 continued pessary application two weeks after visit 3 (visit 4) and during follow up three
441 months after visit 4 (visit 5).

442 The aim of the clinical trial had been to compare the effectiveness of two different types of
443 pessary. The results and the taxonomic composition of the vaginal microbial communities
444 have been reported (5). For the metatranscriptome analysis reported here, we chose a subset
445 of 14 patients from the clinical trial. These 14 patients consisted of two groups named “with
446 response to treatment” (n = 8) and “no response to treatment” (n = 6) (Fig. 1). Among the

447 eight patients who responded to treatment, six had no recurrence and two experienced
448 recurrence during the three months follow-up. For the analysis of lack of response to
449 metronidazole, samples from all 14 patients were analyzed at two timepoints, acute BV (visit
450 1) and 7 to 28 days after antibiotic treatment (visit 2) (28 samples in total). For the analysis of
451 recurrence, samples from all 5 visits were analyzed for 4 patients (two without recurrence and
452 two with) (20 samples in total). These four patients all received the commercially available
453 lactic acid pessary after metronidazole therapy at visit 3 and 4. Nugent score >6 was used to
454 determine BV status since it is considered the gold standard for BV diagnosis (55) (Table S1
455 sheet 1). The BV status at visit 5 was determined by Amsel criteria as there was no Nugent
456 score available at that timepoint. The sample ID was obtained by concatenating the patient ID
457 and letters "a" to "e" indicating visit 1 to 5.

458 **Sample collection and transport**

459 Vaginal fluid was obtained by infusing 2 ml of saline solution into the vagina followed by
460 rotation against the vaginal wall with a speculum and then collecting the vaginal fluid with a
461 syringe. Approximately 700 µl were immediately transferred to a tube containing 2 ml
462 RNAprotect (Qiagen, Germany). Tubes were immediately frozen at -20°C, transported at -
463 20°C within a week and stored at -70°C.

464 **RNA extraction and mRNA enrichment**

465 RNA was extracted from 1 ml vaginal fluid suspension using the MO BIO
466 PowerMicrobiome™ RNA Isolation Kit (Qiagen, Germany) with pretreatment: Vaginal fluid
467 was centrifuged at 13,000 rpm for 1 minute. The pellet was resuspended in MoBio lysis buffer
468 and this suspension was added to the supplied bead tubes filled with 500 µl ice-cold
469 Phenol:Chloroform:Isoamyl Alcohol solution (Carl Roth, Germany). The bead-suspension

470 mix was shaken at 5 m/s for 1 minute in 3 intervals which were 2 minutes apart using the MO
471 BIO PowerLyzer™ (Qiagen, Germany). After centrifugation for 1 minute at 13,000 rpm and
472 4°C the upper phase containing the RNA was further processed according to the
473 manufacturer's instructions including DNAse I treatment. RNA was eluted in 100µl nuclease
474 free water and vacuum concentrated to 50 µl. The Ribo-Zero Gold rRNA Removal Kit
475 (Epidemiology) by Illumina (USA) was then used for mRNA enrichment with ethanol
476 precipitation according to the manufacturer's instructions. Integrity of RNA was evaluated
477 using a Bioanalyzer 2100 (Agilent, Germany).

478 **Library preparation, sequencing and preprocessing of sequencing data**

479 Paired-end mRNA Illumina sequencing libraries were constructed with the Script Seq
480 Illumina Kit. Strand specific paired end sequencing was performed on the HiSeq 2500
481 Sequencer to yield 2 × 110 bp paired-end reads. Primers and sequencing adaptors were
482 removed from raw sequencing data, followed by clipping the bases with quality score < 20
483 from the reads using Fastq-Mcf (56). After clipping, the remaining reads shorter than 50 were
484 removed. Thereafter, the ribosomal RNA reads were eliminated using SortMeRNA v2.0 (57)
485 with the default parameters.

486 **Taxonomy assignment using Kraken**

487 Kraken (27), an accurate and ultra-fast taxonomy assignment tool for metagenomes was used
488 to determine the taxonomic composition of the metatranscriptome data. Kraken uses the K-
489 mer strategy and the lowest common ancestor (LCA) algorithm to affiliate a given read to a
490 taxon. The standard Kraken database with addition of the human genome was used to identify
491 human reads. This standard database consists of prokaryote genomes (2786), virus genomes
492 (4418). The human genome (ver. GRCh38) was additionally downloaded from NCBI.

493 The ref_Genome database contained 163 bacterial genomes from 105 species of bacteria,
494 including 147 genomes from the urogenital subset of the HMP reference genome sequence
495 data (HMRGD). The complete list of reference genomes in the ref_Genome database can be
496 found in Table S1 sheet 3. All results on the taxonomic composition in this study were
497 achieved based on this database.

498 **Short reads alignment by BWA**

499 Kraken was used for taxonomy classification, while BWA was applied to determine the
500 expression of genes. A reference gene database named ref_Gene was constructed which
501 contained the genes from the urogenital tract subset of the HMRGD and the genes from 9
502 additional genomes (Table S1 sheet 4). The genes of *Gardnerella sp.* 26-12, *Gardnerella sp.*
503 30-4 could not be included because only less than half of their CDS are available (around
504 1000 genes). The short reads alignment was performed using BWA with the BWA-MEM (58)
505 algorithm. A mapping seed length of 31 which is much longer than the default seed length 19
506 was applied to achieve reliable alignments. Reads that mapped with mapping quality score
507 (MAPQ) lower than 10 were excluded. MAPQ contains the Phred-scaled posterior probability
508 that the mapping position is wrong (59).

509 **KEGG Orthologous (KO) gene annotation of ref_Gene database**

510 The ref_Gene database was annotated using KEGG prokaryote protein sequences. The KEGG
511 prokaryote protein sequence database represents a non-redundant protein dataset of Bacteria
512 and Archaea on the species level and contains about 7 million non-redundant peptide
513 sequences grouped into 14,390 distinct KO genes. A KO gene contains several genes from
514 different species with similar function. DIAMOND (60), a much faster alternative to
515 BLASTX was applied to map the ref_Gene sequences against the KEGG prokaryote protein

516 sequence database with its “more sensitive mode”. To obtain reliable annotation, only
517 alignments with sequence identity >=50 and E-value <= 1e-5 and query coverage >= 70%
518 were taken into account. By annotating the genes in the ref_Gene database to KO genes, we
519 were able to determine the expression profile of KO genes, and investigate the activity shifts
520 in BV based on differential expression analysis of KO genes. The cumulative dominance
521 analysis and PCA were carried out using Primer 7 (61).

522 **Differential expression (DE) analysis**

523 All differential expression (DE) analyses were performed using the R package edgeR (62).
524 The Benjamini Hochberg (BH) method was used to correct the p value of DE analysis with
525 the false discovery rate (FDR) for multiple comparisons. Genes with FDR smaller than 0.05
526 were considered as significantly differentially regulated. The sample groups defined for each
527 comparison are listed in Table S1 sheet 1.

528 **Detection of putative metronidazole resistance related genes**

529 To detect the expression of previously reported putative metronidazole resistance genes such
530 as recA, recA-mediated autopeptidase (Rma), peroxiredoxin, nitroimidazole resistance protein
531 (NIM), ferredoxin/ferredoxin-NADP reductase (FNR), nitroreductase and ferredoxin, we
532 examined the expression level of these genes for *G. vaginalis* in the vaginal community from
533 patients without response to metronidazole treatment (n = 6) as well as with response (n = 4).
534 As most of these genes do not have corresponding KO genes, we annotated the ref_Gene
535 database based on the sequences of these genes using BLASTN. The sequences were
536 retrieved from ENA by key words of each “ferredoxin, NADPH flavin oxidoreductase,
537 nitroreductase, peroxiredoxin, pyruvate ferredoxin oxidoreductase, recA, nitroimidazole
538 resistance” plus *G. vaginalis*. In total, 155 unique sequences of *G. vaginalis* were obtained for

539 the annotation of ref_Gene database. The identification of duplicate sequences was done by
540 SeqKit (63).

541 **Availability of data and material**

542 The sequencing data have been deposited in the European Nucleotide Archive with accession
543 number PRJEB21446.

544 Authors' contributions

545 This study was designed by IWD and CG. CM and CA provided the clinical samples. RNA
546 extraction and mRNA enrichment was performed by CG. SB prepared cDNA libraries, and
547 performed Illumina sequencing. Z-LD performed all the data analyses. Data interpretation and
548 visualization were done by IWD, Z-LD and CG. Z-LD and CG wrote the manuscript draft,
549 and all authors reviewed the manuscript.

550 Acknowledgements

551 This work was supported by ZIM project grant KF3134201MD3 of the Bundesministerium
552 für Wirtschaft und Energie (BMWi), Germany. The clinical study was funded by Dr. August
553 Wolff GmbH & Co. KG Arzneimittel within the ZIM project KF3134201MD3.

554

555 Reference

556

557 1. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle
558 R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ. 2011.
559 Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A 108 Suppl
560 1:4680-4687. doi:1002611107 [pii];10.1073/pnas.1002611107 [doi].

561 2. van de Wijgert JH, Borgdorff H, Verhelst R, Crucitti T, Francis S, Verstraelen H,
562 Jespers V. 2014. The vaginal microbiota: what have we learned after a decade of
563 molecular characterization? PLoS One 9:e105998. doi:10.1371/journal.pone.0105998
564 [doi];PONE-D-14-20877 [pii].

565 3. Onderdonk AB, Delaney ML, Fichorova RN. 2016. The Human Microbiome during
566 Bacterial Vaginosis. Clin Microbiol Rev 29:223-238. doi:29/2/223
567 [pii];10.1128/CMR.00075-15 [doi].

568 4. Dols JA, Molenaar D, van der Helm JJ, Caspers MP, de KA-B, Schuren FH,
569 Speksnijder AG, Westerhoff HV, Richardus JH, Boon ME, Reid G, de Vries HJ, Kort R.
570 2016. Molecular assessment of bacterial vaginosis by Lactobacillus abundance and
571 species diversity. BMC Infect Dis 16:180. doi:10.1186/s12879-016-1513-3
572 [doi];10.1186/s12879-016-1513-3 [pii].

573 5. Gottschick C, Deng Z-L, Vital M, Masur C, Abels C, Pieper D, Rohde M, Mendling W,
574 Wagner-Dobler I. 2017. Treatment of biofilms in bacterial vaginosis by an amphoteric
575 tenside pessary - clinical study and microbiome analysis. Microbiome 5:119.

576 6. Schellenberg JJ, Patterson MH, Hill JE. 2017. Gardnerella vaginalis diversity and
577 ecology in relation to vaginal symptoms. Res Microbiol 168:837-844. doi:S0923-
578 2508(17)30060-8 [pii];10.1016/j.resmic.2017.02.011 [doi].

579 7. Ahmed A, Earl J, Retchless A, Hillier SL, Rabe LK, Cherpes TL, Powell E, Janto B,
580 Eutsey R, Hiller NL, Boissy R, Dahlgren ME, Hall BG, Costerton JW, Post JC, Hu FZ,
581 Ehrlich GD. 2012. Comparative genomic analyses of 17 clinical isolates of Gardnerella
582 vaginalis provide evidence of multiple genetically isolated clades consistent with
583 subspeciation into genovars. J Bacteriol 194:3922-3937. doi:JB.00056-12
584 [pii];10.1128/JB.00056-12 [doi].

585 8. Hill JE, Goh SH, Money DM, Doyle M, Li A, Crosby WL, Links M, Leung A, Chan D,
586 Hemmingsen SM. 2005. Characterization of vaginal microflora of healthy, nonpregnant
587 women by chaperonin-60 sequence-based methods. Am J Obstet Gynecol 193:682-692.
588 doi:S0002-9378(05)00340-6 [pii];10.1016/j.ajog.2005.02.094 [doi].

589 9. Paramel JT, Schellenberg JJ, Hill JE. 2012. Resolution and characterization of distinct
590 cpn60-based subgroups of Gardnerella vaginalis in the vaginal microbiota. PLoS One
591 7:e43009. doi:10.1371/journal.pone.0043009 [doi];PONE-D-12-12121 [pii].

592 10. Chaban B, Links MG, Jayaprakash TP, Wagner EC, Bourque DK, Lohn Z, Albert AY,
593 van SJ, Reid G, Hemmingsen SM, Hill JE, Money DM. 2014. Characterization of the
594 vaginal microbiota of healthy Canadian women through the menstrual cycle.
595 Microbiome 2:23. doi:10.1186/2049-2618-2-23 [doi];2049-2618-2-23 [pii].

596 11. Albert AY, Chaban B, Wagner EC, Schellenberg JJ, Links MG, van SJ, Reid G,
597 Hemmingsen SM, Hill JE, Money D. 2015. A Study of the Vaginal Microbiome in
598 Healthy Canadian Women Utilizing cpn60-Based Molecular Profiling Reveals Distinct
599 Gardnerella Subgroup Community State Types. PLoS One 10:e0135620.
600 doi:10.1371/journal.pone.0135620 [doi];PONE-D-15-15097 [pii].

601 12. Schellenberg JJ, Paramel JT, Withana GN, Patterson MH, Vaneechoutte M, Hill JE.
602 2016. Gardnerella vaginalis Subgroups Defined by cpn60 Sequencing and Sialidase
603 Activity in Isolates from Canada, Belgium and Kenya. PLoS One 11:e0146510.
604 doi:10.1371/journal.pone.0146510 [doi];PONE-D-15-36020 [pii].

605 13. Bradshaw CS, Morton AN, Garland SM, Horvath LB, Kuzevska I, Fairley CK. 2005.
606 Evaluation of a point-of-care test, BVBlue, and clinical and laboratory criteria for
607 diagnosis of bacterial vaginosis. J Clin Microbiol 43:1304-1308. doi:43/3/1304
608 [pii];10.1128/JCM.43.3.1304-1308.2005 [doi].

609 14. Schuyler JA, Mordechai E, Adelson ME, Sobel JD, Gygax SE, Hilbert DW. 2016.
610 Identification of intrinsically metronidazole-resistant clades of Gardnerella vaginalis.
611 Diagn Microbiol Infect Dis 84:1-3. doi:S0732-8893(15)00360-0
612 [pii];10.1016/j.diagmicrobio.2015.10.006 [doi].

613 15. Bradshaw CS, Pirotta M, De GD, Hocking JS, Morton AN, Garland SM, Fehler G,
614 Morrow A, Walker S, Vodstrcil LA, Fairley CK. 2012. Efficacy of oral metronidazole
615 with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised
616 placebo-controlled double-blind trial. PLoS One 7:e34540.
617 doi:10.1371/journal.pone.0034540 [doi];PONE-D-11-24250 [pii].

618 16. Lofmark S, Edlund C, Nord CE. 2010. Metronidazole is still the drug of choice for
619 treatment of anaerobic infections. Clin Infect Dis 50 Suppl 1:S16-S23.
620 doi:10.1086/647939 [doi].

621 17. Mendz GL, Megraud F. 2002. Is the molecular basis of metronidazole resistance in
622 microaerophilic organisms understood? Trends Microbiol 10:370-375.
623 doi:S0966842X02024058 [pii].

624 18. Lofmark S, Fang H, Hedberg M, Edlund C. 2005. Inducible metronidazole resistance
625 and nim genes in clinical Bacteroides fragilis group isolates. Antimicrob Agents
626 Chemother 49:1253-1256. doi:49/3/1253 [pii];10.1128/AAC.49.3.1253-1256.2005
627 [doi].

628 19. Steffens LS, Nicholson S, Paul LV, Nord CE, Patrick S, Abratt VR. 2010. Bacteroides
629 fragilis RecA protein overexpression causes resistance to metronidazole. Res Microbiol
630 161:346-354. doi:S0923-2508(10)00085-9 [pii];10.1016/j.resmic.2010.04.003 [doi].

631 20. Hilbert DW, Smith WL, Paulish-Miller TE, Chadwick SG, Toner G, Mordechai E,
632 Adelson ME, Sobel JD, Gygax SE. 2016. Utilization of molecular methods to identify
633 prognostic markers for recurrent bacterial vaginosis. Diagn Microbiol Infect Dis.
634 doi:S0732-8893(16)30197-3 [pii];10.1016/j.diagmicrobio.2016.07.003 [doi].

635 21. Ferreira CST, Donders GG, Parada CMGL, Tristao ADR, Fernandes T, da Silva MG,
636 Marconi C. 2017. Treatment failure of bacterial vaginosis is not associated with higher
637 loads of Atopobium vaginae and Gardnerella vaginalis. J Med Microbiol 66:1217-1224.
638 doi:10.1099/jmm.0.000561 [doi].

639 22. Macklaim JM, Fernandes AD, Di Bella JM, Hammond JA, Reid G, Gloor GB. 2013.
640 Comparative meta-RNA-seq of the vaginal microbiota and differential expression by

641 Lactobacillus iners in health and dysbiosis. Microbiome 1:12. doi:2049-2618-1-12
642 [pii];10.1186/2049-2618-1-12 [doi].

643 23. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath
644 LB, Kuzevska I, Fairley CK. 2006. High recurrence rates of bacterial vaginosis over the
645 course of 12 months after oral metronidazole therapy and factors associated with
646 recurrence. J Infect Dis 193:1478-1486. doi:JID36020 [pii];10.1086/503780 [doi].

647 24. Sobel JD, Schmitt C, Meriwether C. 1993. Long-term follow-up of patients with
648 bacterial vaginosis treated with oral metronidazole and topical clindamycin. J Infect Dis
649 167:783-784.

650 25. Turovskiy Y, Sutyak NK, Chikindas ML. 2011. The aetiology of bacterial vaginosis. J
651 Appl Microbiol 110:1105-1128. doi:10.1111/j.1365-2672.2011.04977.x [doi].

652 26. Petrova MI, Reid G, Vaneechoutte M, Lebeer S. 2016. Lactobacillus iners: Friend or
653 Foe? Trends Microbiol. doi:S0966-842X(16)30181-0 [pii];10.1016/j.tim.2016.11.007
654 [doi].

655 27. Wood DE, Salzberg SL. 2014. Kraken: ultrafast metagenomic sequence classification
656 using exact alignments. Genome Biol 15:R46. doi:gb-2014-15-3-r46 [pii];10.1186/gb-
657 2014-15-3-r46 [doi].

658 28. The Human Microbiome Project Consortium. 2012. A framework for human
659 microbiome research. Nature 486:215-221. doi:10.1038/nature11209.

660 29. Malki K, Shapiro JW, Price TK, Hilt EE, Thomas-White K, Sircar T, Rosenfeld AB,
661 Kuffel G, Zilliox MJ, Wolfe AJ, Putonti C. 2016. Genomes of Gardnerella Strains
662 Reveal an Abundance of Prophages within the Bladder Microbiome. PLoS One
663 11:e0166757. doi:10.1371/journal.pone.0166757 [doi];PONE-D-16-20473 [pii].

664 30. Deng ZL, Szafranski SP, Jarek M, Bhuju S, Wagner-Dobler I. 2017. Dysbiosis in
665 chronic periodontitis: Key microbial players and interactions with the human host. Sci
666 Rep 7:3703. doi:10.1038/s41598-017-03804-8 [doi];10.1038/s41598-017-03804-8 [pii].

667 31. Hellinga HW, Evans PR. 1985. Nucleotide sequence and high-level expression of the
668 major Escherichia coli phosphofructokinase. Eur J Biochem 149:363-373.

669 32. Arnold RJ, Reilly JP. 1999. Observation of Escherichia coli ribosomal proteins and their
670 posttranslational modifications by mass spectrometry. Anal Biochem 269:105-112.
671 doi:S0003-2697(98)93077-9 [pii];10.1006/abio.1998.3077 [doi].

672 33. Bubunenko M, Baker T, Court DL. 2007. Essentiality of ribosomal and transcription
673 antitermination proteins analyzed by systematic gene replacement in Escherichia coli. J
674 Bacteriol 189:2844-2853. doi:JB.01713-06 [pii];10.1128/JB.01713-06 [doi].

675 34. Webb AJ, Homer KA, Hosie AH. 2008. Two closely related ABC transporters in
676 Streptococcus mutans are involved in disaccharide and/or oligosaccharide uptake. J
677 Bacteriol 190:168-178. doi:JB.01509-07 [pii];10.1128/JB.01509-07 [doi].

678 35. Shipkowski S, Brenchley JE. 2006. Bioinformatic, genetic, and biochemical evidence
679 that some glycoside hydrolase family 42 beta-galactosidases are arabinogalactan type I
680 oligomer hydrolases. Appl Environ Microbiol 72:7730-7738. doi:AEM.01306-06
681 [pii];10.1128/AEM.01306-06 [doi].

682 36. Pleckaityte M, Zilnyte M, Zvirbliene A. 2012. Insights into the CRISPR/Cas system of
683 Gardnerella vaginalis. BMC Microbiol 12:301. doi:1471-2180-12-301
684 [pii];10.1186/1471-2180-12-301 [doi].

685 37. Ojala T, Kankainen M, Castro J, Cerca N, Edelman S, Westerlund-Wikstrom B, Paulin
686 L, Holm L, Auvinen P. 2014. Comparative genomics of Lactobacillus crispatus suggests
687 novel mechanisms for the competitive exclusion of Gardnerella vaginalis. BMC
688 Genomics 15:1070. doi:1471-2164-15-1070 [pii];10.1186/1471-2164-15-1070 [doi].

689 38. Hertzberger R, Arents J, Dekker HL, Pridmore RD, Gysler C, Kleerebezem M, de
690 Mattos MJ. 2014. H(2)O(2) production in species of the Lactobacillus acidophilus
691 group: a central role for a novel NADH-dependent flavin reductase. Appl Environ
692 Microbiol 80:2229-2239. doi:AEM.04272-13 [pii];10.1128/AEM.04272-13 [doi].

693 39. Gelber SE, Aguilar JL, Lewis KL, Ratner AJ. 2008. Functional and phylogenetic
694 characterization of Vaginolysin, the human-specific cytolysin from Gardnerella
695 vaginalis. J Bacteriol 190:3896-3903. doi:JB.01965-07 [pii];10.1128/JB.01965-07 [doi].

696 40. Frank JA, Reich CI, Sharma S, Weisbaum JS, Wilson BA, Olsen GJ. 2008. Critical
697 evaluation of two primers commonly used for amplification of bacterial 16S rRNA
698 genes. Appl Environ Microbiol 74:2461-2470. doi:AEM.02272-07
699 [pii];10.1128/AEM.02272-07 [doi].

700 41. Srinivasan S, Hoffman NG, Morgan MT, Matsen FA, Fiedler TL, Hall RW, Ross FJ,
701 McCoy CO, Bumgarner R, Marrazzo JM, Fredricks DN. 2012. Bacterial communities in
702 women with bacterial vaginosis: high resolution phylogenetic analyses reveal
703 relationships of microbiota to clinical criteria. PLoS One 7:e37818.
704 doi:10.1371/journal.pone.0037818 [doi];PONE-D-12-04403 [pii].

705 42. Ling Z, Kong J, Liu F, Zhu H, Chen X, Wang Y, Li L, Nelson KE, Xia Y, Xiang C.
706 2010. Molecular analysis of the diversity of vaginal microbiota associated with bacterial
707 vaginosis. BMC Genomics 11:488. doi:1471-2164-11-488 [pii];10.1186/1471-2164-11-
708 488 [doi].

709 43. Oakley BB, Fiedler TL, Marrazzo JM, Fredricks DN. 2008. Diversity of human vaginal
710 bacterial communities and associations with clinically defined bacterial vaginosis. Appl
711 Environ Microbiol 74:4898-4909. doi:AEM.02884-07 [pii];10.1128/AEM.02884-07
712 [doi].

713 44. Gerrits MM, van der Wouden EJ, Bax DA, van Zwet AA, van Vliet AH, de JA, Kusters
714 JG, Thijs JC, Kuipers EJ. 2004. Role of the rdxA and frxA genes in oxygen-dependent
715 metronidazole resistance of Helicobacter pylori. J Med Microbiol 53:1123-1128.
716 doi:10.1099/jmm.0.45701-0 [doi].

717 45. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, Barrangou R,
718 Brouns SJ, Charpentier E, Haft DH, Horvath P, Moineau S, Mojica FJ, Terns RM, Terns
719 MP, White MF, Yakunin AF, Garrett RA, van der Oost J, Backofen R, Koonin EV.
720 2015. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev
721 Microbiol 13:722-736. doi:nrmicro3569 [pii];10.1038/nrmicro3569 [doi].

722 46. Doudna JA, Charpentier E. 2014. Genome editing. The new frontier of genome
723 engineering with CRISPR-Cas9. Science 346:1258096. doi:346/6213/1258096
724 [pii];10.1126/science.1258096 [doi].

725 47. Blackwell AL. 1999. Vaginal bacterial phaginosis? Sex Transm Infect 75:352-353.

726 48. Westra ER, Buckling A, Fineran PC. 2014. CRISPR-Cas systems: beyond adaptive
727 immunity. Nat Rev Microbiol 12:317-326. doi:nrmicro3241 [pii];10.1038/nrmicro3241
728 [doi].

729 49. Babu M, Beloglazova N, Flick R, Graham C, Skarina T, Nocek B, Gagarinova A,
730 Pogoutse O, Brown G, Binkowski A, Phanse S, Joachimiak A, Koonin EV, Savchenko
731 A, Emili A, Greenblatt J, Edwards AM, Yakunin AF. 2011. A dual function of the
732 CRISPR-Cas system in bacterial antivirus immunity and DNA repair. Mol Microbiol
733 79:484-502. doi:10.1111/j.1365-2958.2010.07465.x [doi].

734 50. Belizario JE, Napolitano M. 2015. Human microbiomes and their roles in dysbiosis,
735 common diseases, and novel therapeutic approaches. Front Microbiol 6:1050.
736 doi:10.3389/fmicb.2015.01050 [doi].

737 51. France MT, Mendes-Soares H, Forney LJ. 2016. Genomic Comparisons of
738 Lactobacillus crispatus and Lactobacillus iners Reveal Potential Ecological Drivers of
739 Community Composition in the Vagina. Appl Environ Microbiol 82:7063-7073.
740 doi:AEM.02385-16 [pii];10.1128/AEM.02385-16 [doi].

741 52. Rampersaud R, Planet PJ, Randis TM, Kulkarni R, Aguilar JL, Lehrer RI, Ratner AJ.
742 2011. Inerolysin, a cholesterol-dependent cytolysin produced by Lactobacillus iners. J
743 Bacteriol 193:1034-1041. doi:JB.00694-10 [pii];10.1128/JB.00694-10 [doi].

744 53. O'Hanlon DE, Moench TR, Cone RA. 2011. In vaginal fluid, bacteria associated with
745 bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC
746 Infect Dis 11:200. doi:1471-2334-11-200 [pii];10.1186/1471-2334-11-200 [doi].

747 54. Vaneechoutte M. 2017. Lactobacillus iners, the unusual suspect. Res Microbiol
748 168:826-836. doi:S0923-2508(17)30151-1 [pii];10.1016/j.resmic.2017.09.003 [doi].

749 55. Mohammadzadeh F, Dolatian M, Jorjani M, Alavi MH. 2014. Diagnostic value of
750 Amsel's clinical criteria for diagnosis of bacterial vaginosis. Glob J Health Sci 7:8-14.
751 doi:10.5539/gjhs.v7n3p8 [doi].

752 56. Aronesty E. 2011. ea-utils: Command-line tools for processing biological sequencing
753 data. Durham, NC: Expression Analysis.

754 57. Kopylova E, Noe L, Touzet H. 2012. SortMeRNA: fast and accurate filtering of
755 ribosomal RNAs in metatranscriptomic data. Bioinformatics 28:3211-3217. doi:bts611
756 [pii];10.1093/bioinformatics/bts611 [doi].

757 58. Li H. 2013. Aligning sequence reads, clone sequences and assembly contigs with BWA-
758 MEM. arXiv preprint arXiv:1303 3997.

759 59. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G,
760 Durbin R. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics
761 25:2078-2079. doi:btp352 [pii];10.1093/bioinformatics/btp352 [doi].

762 60. Buchfink B, Xie C, Huson DH. 2015. Fast and sensitive protein alignment using
763 DIAMOND. Nat Methods 12:59-60. doi:nmeth.3176 [pii];10.1038/nmeth.3176 [doi].

764 61. Clarke KR. 1993. Non-parametric multivariate analyses of changes in community
765 structure. Austral ecology 18:117-143.

766 62. Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: a Bioconductor package for
767 differential expression analysis of digital gene expression data. Bioinformatics 26:139-
768 140. doi:btp616 [pii];10.1093/bioinformatics/btp616 [doi].

769 63. Shen W, Le S, Li Y, Hu F. 2016. SeqKit: A Cross-Platform and Ultrafast Toolkit for
770 FASTA/Q File Manipulation. PLoS One 11:e0163962.
771 doi:10.1371/journal.pone.0163962 [doi];PONE-D-16-20820 [pii].

772

773

774 ## Figures, tables and additional files

775 **Fig. 1: Study design and taxonomic composition of vaginal fluid metatranscriptomes in**
776 **BV and after treatment with metronidazole. (A). Time course of the clinical study. (B)**
777 **Taxonomic composition of the metatranscriptome at visit 1 (diagnosis) and visit 2 (after**
778 **metronidazole therapy). (C) Cumulative dominance of the vaginal microbiota in BV and**
779 **non-BV. (D) The subspecies composition of the *G. vaginalis* sub-community.** Species with
780 average relative abundance smaller than 0.5% were grouped into "Others". The red dot on top
781 of the samples indicates BV. The digits indicate the patient ID, while the letters a-b denote
782 visit 1-2. After the first sampling at visit 1 the patients were treated with metronidazole. Total
783 putative bacterial mRNA reads were mapped to the ref_Genome database using Kraken (see

784 Methods for details). BV status was determined by Nugent score. In C, the "BV" and "NBV"
785 in the parenthesis indicate BV and non-BV, respectively.

786 **Fig. 2: Average taxonomic composition of vaginal fluid samples in BV determined by**
787 **16S rRNA amplicon sequencing (A) and metatranscriptome sequencing (B).** (A)
788 Amplicon sequencing was performed as described in our previous study (5) using primers V1-
789 V2. (B) The taxonomy was assigned based on all cleaned reads after removal of human reads
790 using Kraken and the ref_Genome database. The top 12 most abundant taxa for each approach
791 are shown in A and B. Relative average abundance was calculated based on all mapped reads.
792 Mean and standard error are shown.

793 **Fig. 3: Principal components analysis (PCA) based on taxonomic profiles and activity**
794 **profiles in BV and after metronidazole therapy (non-BV). (A) The PCA plot based on**
795 **taxonomic profile using 16S rRNA gene sequencing. (B) The PCA based on taxonomic**
796 **composition determined by metatranscriptome. (C) The PCA plot based on KO gene**
797 **expression profile.** The communities at visit 1 (BV) and visit 2 (after metronidazole therapy,
798 non-BV) from 14 patients are shown. In the PCA biplots of taxonomy composition (Fig. 3A-
799 B), the taxa with multivariate (multiple) correlation higher than 0.3 are illustrated, while for
800 PCA (Fig. 3C) of KO profiles the KO genes with correlation >0.2 are shown.

801

802 **Fig. 4: Changes in gene expression of *G. vaginalis* in patients responding to antibiotic**
803 **treatment compared to non-responders. (A) Expression of putative metronidazole**
804 **resistance associated genes of *G. vaginalis* in vaginal fluid microbiota. (B) Differential**
805 **expression of KO genes: Seven *cas* genes of *G. vaginalis* were highly up-regulated in**
806 **communities from patients who did not respond to the treatment**. (A) The expression
807 value was calculated based on relative abundance of reads mapped onto *G. vaginalis* using

808 BWA. “NR1” (No Response 1) indicates the BV samples from six patients that did not
809 respond to metronidazole treatment; “WR1” (With Response 1) represents the BV samples
810 from four patients which afterwards responded to metronidazole. The dotplot illustrates the
811 log2FC of the corresponding activity between *G. vaginalis* from non-responders and
812 responders. The values in the heatmap were scaled using Z-sore. In the figure legend, “exp.”
813 indicates the relative expression level. (B) “NR1” samples were compared with “WR1”. KO
814 genes with FDR <= 0.05 are colored in red or turquoise (significantly differentially regulated)
815 while FDR > 0.05 are in grey.

816 **Fig. 5: Shifts in the vaginal microbiome over 3 months. (A) Taxonomic composition of**
817 **the metatranscriptome in two patients that were stably non-BV (without recurrence)**
818 **and two patients that experienced recurrence. (B) PCA of activity profiles based on KO**
819 **genes from the same patients. (C) Gene expression *in vivo* of *L. crispatus* and *L. iners*.** (A)
820 Acute BV and recurrence according to Nugent score are indicated as red dot. (B) Two women
821 with recurrence (pink and blue color range) and two women without recurrence (green and
822 orange color range) are shown. In the figure legend, BV indicates timepoint with BV, “R”
823 indicates the recurrence and “H” represents health. The green and blue circles highlight
824 healthy clusters, respectively, while the red circle highlights samples from BV. The arrows
825 denote the temporal shifts of the communities during the treatment. (C**)** The Venn diagram
826 indicates the unique KO genes of *L. crispatus* and *L. iners* as well as their shared KO genes.
827 The innermost ring denotes the expression of KO genes by log2CPM, the outer ring illustrates
828 the fold change of the expression of KO genes between *L. crispatus* dominated communities
829 and *L. iners* dominated communities by log2FC. The KO genes are in descending order based
830 on log2CPM. The small red triangles mark the inerolysin and hemolysin C genes, while blue

831 and green triangles mark the genes encoding proteins involved in the production of D-lactic

832 acid and hydrogen peroxide, respectively.

833

834 ## Supplementary Information

835 **Fig. S1: Taxonomic composition of communities on the species level determined by**
836 **metatranscriptome sequencing in non-BV and BV.** The species present in at least 2
837 samples with relative abundance >1% are shown. The *Gardnerella* bladder isolates are
838 illustrated separately from *G. vaginalis*. The sample name in red indicates the first BV
839 incidence of patients with recurrence and purple depicts the second incidence.

840 **Supplementary Table S1: All supplementary data**

841 **Sheet 1: Sample description**

842 **Sheet 2: Read summary**

843 **Sheet 3: Genomes in the ref_Genome database for taxonomic assignment**

844 **Sheet 4: Genomes in the ref_Gene database with a total of 301,323 genes for functional**
845 **assignment with BWA**

846 **Sheet 5: Species composition determined by Kraken based on the ref_Genome database**
847 **for taxonomic assignment**

848 **Sheet 6: Comparison of the community composition determined by 16S rRNA gene**
849 **amplicon sequencing (V1-V2) and metatranscriptome sequencing**

850 **Sheet 7: Gene expression based on the ref_Gene database for functional assignment with**
851 **KO annotation**

852 **Sheet 8: The differential expression of KO genes between *L. crispatus* and *L. iners***

853 **Sheet 9: Expression of metronidazole activation and resistance associated genes in *G.***

854 ***vaginalis***

855 **Sheet 10: Differential expression of KO genes of *G. vaginalis* from communities without**

856 **response to metronidazole treatment compared to those with response**


A
Metronidazole
Pessary
visit1
visit2
visit3
visit4
visit5
1-2 weeks
1 week
2 weeks
To 3 months
a
b
c
d
e
B
with response to treatment
no response to treatment
% abundance
Gardnerella vaginalis
Sneathia amnii
Sneathia sanguinegens
Atopobium vaginae
Lactobacillus crispatus
Lactobacillus iners
Lactobacillus gasseri
Lactobacillus jensenii
Peptostreptococcus anaerobius
Peptoniphilus lacrimalis
Mobiluncus mulieris
Prevotella amnii
Prevotella bivia
Prevotella timonensis
Others
C
% Cumulative dominance
Species rank
04_001_a (BV)
04_001_b (NBV)
05_012_a (BV)
05_012_b (NBV)
06_004_a (BV)
06_004_b (NBV)
06_010_a (BV)
06_010_b (NBV)
08_003_a (BV)
08_003_b (NBV)
08_006_a (BV)
08_006_b (NBV)
13_019_a (BV)
13_019_b (NBV)
13_022_a (BV)
13_022_b (NBV)
average (BV)
average (NBV)
D
response
no response
% abundance
G. vaginalis
Subgroup A
Subgroup B
Subgroup C
Subgroup D
Ambiguous
unclassified


A
amplicon
Atopobium vaginae
Sneathia amnii
Veillonellaceae
Lactobacillus iners
Prevotella timonensis
Sneathia sanguinegens
Gardnerella vaginalis
Prevotella bivia
Parvimonas
Clostridiales BVAB2
Prevotella amnii
Aerococcus christensenii
0
20
40
% Abundance
B
metaT
Gardnerella vaginalis
Atopobium vaginae
Sneathia amnii
Prevotella timonensis
Lactobacillus iners
Sneathia sanguinegens
Prevotella amnii
Prevotella bivia
Mobiluncus mulieris
Peptoniphilus lacrimalis
Prevotella melaninogenica
Peptostreptococcus anaerobius
0
20
40
% Abundance


A
taxonomy composition - amplicon
Lactobacillus iners
Prevotella bivia
Gardnerella vaginalis
Atopobium vaginae
Veillonellaceae
Prevotella timonensis
Sneathia amnii
PC2 (12.4%)
PC1 (45.7%)
B
taxonomy composition - metaT
Lactobacillus iners
Gardnerella vaginalis
Atopobium vaginae
Sneathia amnii
Lactobacillus crispatus
PC2 (14.4%)
PC1 (47.2%)
C
KO profile - metaT
BV
non-BV
pfkA
msmE
rpsI
rpmF
rplU
cycB
PC2 (15.5%)
PC1 (32.4%)

A


NR1
WR1
NR1 vs. WR1
ferredoxin
FNR
nitroreductase
peroxiredoxin
RecA
Rma
NIM
05_001_a
06_001_a
06_006_a
07_001_a
15_006_a
17_004_a
04_001_a
06_010_a
08_006_a
13_019_a
13_022_a
−2
−1
0
log2FC
Z-score
2
0
−2
% exp.
0.1
0.2
0.3

B


fucO
cas3
adhP
K07729
galT
K06999
ABC.GGU.P
NEU1
fucP
dinJ
RP−L3
rpoA
casB
casA
casD
cas2
casC
cas1
2.5
2.0
1.5
1.0
0.5
0.0
−log10FDR
−5
0
5
10
log2 fold change
Regulation
Down
Up
log2CPM
6
8
10
12


A
without recurrence
recurrence
% abundance
100
75
50
25
0
08_006_a
08_006_b
08_006_c
08_006_d
08_006_e
13_019_a
13_019_b
13_019_c
13_019_d
13_019_e
04_001_a
04_001_b
04_001_c
04_001_d
04_001_e
06_004_a
06_004_b
06_004_c
06_004_d
06_004_e
B
PC3 (6.8%)
PC2 (18.5%)
PC1 (37%)
1
2
3
4
04_001
vis1-BV
vis2-N
vis3-N
vis4-N
vis5-R
06_004
vis1-BV
vis2-N
vis3-R
vis4-N
vis5-N
08_006
vis1-BV
vis2-N
vis3-N
vis4-N
vis5-N
13_019
vis1-BV
vis2-N
vis3-N
vis4-N
vis5-N
C
L. iners unique
L. cirspatus unique
L. iners
L. crispatus
58
569
244
Common